REFERENCES
1. Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJM. The future of precision oncology. Int J Mol Sci. 2023;24:12613.
2. Chang TG, Park S, Schäffer AA, Jiang P, Ruppin E. Hallmarks of artificial intelligence contributions to precision oncology. Nat Cancer. 2025;6:417-31.
3. Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286-7:18-24.
4. Srivastava R. Applications of artificial intelligence multiomics in precision oncology. J Cancer Res Clin Oncol. 2023;149:503-10.
5. Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. NPJ Precis Oncol. 2019;3:6.
6. Narote S, Desai SA, Patel VP, Deshmukh R, Raut N, Dapse S. Identification of new immune target and signaling for cancer immunotherapy. Cancer Genet. 2025;294-5:57-75.
7. Planchard D, Cozic N, Mosele MF, et al. Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study. Cancer Cell. 2026;44:1147-59.e6.
8. Liu H, Li Y, Karsidag M, Tu T, Wang P. Technical and biological biases in bulk transcriptomic data mining for cancer research. J Cancer. 2025;16:34-43.
9. Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann Oncol. 2021;32:1148-56.
10. Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT Clinical Trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 2024;42:1738-44.
11. Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402:1423-33.
12. Tolaney SM, Cardillo TM, Chou CC, Dornan C, Faris M. The mode of action and clinical outcomes of sacituzumab govitecan in solid tumors. Clin Cancer Res. 2025;31:1390-9.
